Bottom line
N-Acetyl Semax Amidate is a chemically modified variant of Semax bearing N-terminal acetylation and C-terminal amidation, intended to improve metabolic stability and blood-brain barrier penetration. It is not an approved drug in any jurisdiction and has no published human clinical trials. The scientific literature base is limited to animal studies. The compound is distinct from Semax (an approved medicine in Russia) and should not be assumed equivalent in safety, efficacy, or How a substance is absorbed, distributed, metabolized, and eliminated by the body; atlas pages report pharmacokinetic data such as half-life, metabolism, and clearance. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表.
Identity and composition
| Field | Verified information |
|---|---|
| Preferred name | N-Acetyl Semax Amidate |
| Key aliases | NA-Semax-A, Acetyl-Semax-Amidate, Ac-MEHF-PGP-NH₂ |
| Molecular/sequence identity | Ac-L-Met-L-Glu-L-His-L-Phe-L-Pro-L-Gly-L-Pro-NH₂ |
| Modifications/form | N-terminal acetyl cap; C-terminal amidation; both termini blocked |
| Stable identifiers | CAS 2920938-90-3 (related); no DrugBank or UNII assigned; The record number of a compound in PubChem, the atlas's primary structure-asset source. A registry record or depiction does not authenticate a commercial sample. 定义来源: Identity and structure assets methodology · 术语表: 172638603 |
| Identity caveats | Not equivalent to Semax — terminal modifications alter PK/PD profile; the CAS entry is broadly associated and cross-referencing is uncertain; no regulatory body has reviewed this exact entity |
Development and approval status
| Jurisdiction | Status and indication | Product/source | As of |
|---|---|---|---|
| FDA (US) | Not approved | — | 2026-08 |
| EMA (EU) | Not approved | — | 2026-08 |
| Russia | Not approved as a separate entity | — | 2026-08 |
| Registers reviewed | No FDA-approved product or EMA-authorized medicine identified; status elsewhere requires a current national-register check | — | 2026-08 |
- UNITED STATES
- FDA (US): Not approved
- EU/EEA
- EMA (EU): Not approved
- UNITED KINGDOM
- No UNITED KINGDOM row is present in the source status table
- OTHER DOCUMENTED
- Russia: Not approved as a separate entity; Registers reviewed: No FDA-approved product or EMA-authorized medicine identified; status elsewhere requires a current national-register check
Sport status: WADA: not specifically listed; may be prohibited under category S0 (non-approved substances) — athletes should verify
Mechanism and pharmacology
No published mechanism-of-action studies specific to the amidated form were identified at the time of search. By analogy to Semax, it may modulate melanocortin receptors and upregulate neurotrophins, but the terminal modifications alter receptor interaction, metabolism, and distribution. The claimed improved stability is based on general medicinal-chemistry principles rather than compound-specific published data.
Evidence by claim
| Claim/indication | Stage | Grade | Best human evidence | Main result | Important limitations |
|---|---|---|---|---|---|
| Nootropic / cognitive enhancement | Research chemical | E | None | No human data; extrapolation from Semax only | No compound-specific human trials |
| Improved stability vs Semax | Mechanistic hypothesis | E | Terminal modifications make altered stability plausible | No direct quantitative result established | No peer-reviewed comparative PK study identified |
Text alternative for the claim-evidence diagram. Each grade is defined below:
- A — Established for a specific labeled use
- 0 claims
- B — Moderate human evidence
- 0 claims
- C — Preliminary human evidence
- 0 claims
- D — Preclinical only
- 0 claims
- E — Anecdotal/marketing claim
- 2 claims: Nootropic / cognitive enhancement; Improved stability vs Semax
- X — Evidence contradicts or does not support the claim
- 0 claims
Key studies
No published human studies were identified for N-Acetyl Semax Amidate specifically. Animal and in vitro data are proprietary, pre-publication, or held by research-chemical suppliers without independent peer review.
Dose and administration evidence
No approved labeled regimen
No established or recommended human dose.
Studied regimens (not recommendations)
No published human dose data.
What is not established
Any safe or effective human dose
How a substance is absorbed, distributed, metabolized, and eliminated by the body; atlas pages report pharmacokinetic data such as half-life, metabolism, and clearance. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 in any species outside limited animal data
Difference in clinical effect from Semax
Manufacturing consistency across suppliers
Safety
Established label risks
No regulatory safety assessment exists.
Human-study signals
No human data available.
Unknowns and product-quality risks
All safety dimensions are unknown: acute toxicity, chronic toxicity, mutagenicity, reproductive toxicity, drug interactions, and immunogenicity. Products sold for research use lack regulatory oversight, sterility assurance, identity verification, and dose consistency. Reports of adulteration and mislabelling are endemic in the research chemical market.
Interactions and special populations
No data exist. All interactions and special-population considerations are unknown.
Regulatory, compounding, and sport notes
The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. 定义来源: WADA and sport regulation brief · 术语表: not specifically listed; may be prohibited under category WADA Prohibited List class S0 (non-approved substances): pharmacological substances not addressed elsewhere in the list and with no current approval by any governmental regulatory health authority for human therapeutic use. 定义来源: WADA and sport regulation brief · 术语表 (non-approved substances) — athletes should verify
US DEA: not scheduled
Not identified on the FDA Sections of the US Food, Drug, and Cosmetic Act covering traditional compounding exemptions (503A) and outsourcing-facility compounding (503B). Under 503A, qualification conditions include a patient-specific prescription requirement; under 503B, conditions cover facility registration and bulk-substance eligibility. 定义来源: United States regulation brief · 术语表 bulks list searched for this review; other compounding and pharmacy-law questions are jurisdiction- and product-specific
No registered manufacturer or pharmaceutical product
Evidence gaps
Zero published human trials of any design
No peer-reviewed How a substance is absorbed, distributed, metabolized, and eliminated by the body; atlas pages report pharmacokinetic data such as half-life, metabolism, and clearance. 定义来源: Neutral gloss; usage context: Routes, devices, and absorption primer · 术语表 or pharmacodynamic data specific to the amidated form
No regulatory filings anywhere
Safety profile completely uncharacterised
No independent chemical reference standard available
Search notes
Databases and registries: PubMed, PubChem, CAS Scifinder, ClinicalTrials.gov, Google Scholar
Search terms: N-Acetyl Semax Amidate, NA-Semax-A, acetylated semax amidated
Last searched: 2026-08-06
Inclusion emphasis: compound-specific human or animal data; regulatory records
Sources
PubChem. N-Acetyl Semax Amidate exact-name record (CID 172638603). https://pubchem.ncbi.nlm.nih.gov/compound/172638603
CAS 2920938-90-3. https://commonchemistry.cas.org/detail?cas_rn=2920938-90-3
Global Substance Registration System (GSRS). https://gsrs.ncats.nih.gov/
Vendor listings (e.g., Peptide Sciences, Limitless Biotech) — document market presence but not safety or efficacy
